NXC-201 is currently being evaluated in AL amyloidosis within a Phase Ib/II trial, but Immix plans to test it in other, undisclosed serious diseases.

Even though oncology segment revenue inched up just 1 percent year over year, the firm lifted full-year expectations slightly ...